Press coverage about Innoviva (NASDAQ:THRX) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Innoviva earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.7994867244076 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Innoviva (NASDAQ THRX) remained flat at $9.81 on Friday. The company has a 50-day moving average of $9.81 and a 200 day moving average of $11.67. Innoviva has a 12 month low of $6.36 and a 12 month high of $21.16.

TRADEMARK VIOLATION WARNING: “Innoviva (THRX) Receiving Somewhat Favorable Press Coverage, Analysis Finds” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.watchlistnews.com/innoviva-thrx-receiving-somewhat-favorable-press-coverage-analysis-finds/1474429.html.

Innoviva Company Profile

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Insider Buying and Selling by Quarter for Innoviva (NASDAQ:THRX)

Receive News & Ratings for Innoviva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.